Webdisclosure.com

Search

Polyphor AG


POLYPHOR AG 
06/09/2018 07:00
EQS-Adhoc: Polyphor announces financial results for the first half 2018
Lire la news
Voir tous les communiqués de Polyphor AG
POLYPHOR AG 
06/09/2018 06:45
EQS-Adhoc: Novo Holdings invests CHF 6.8 Million in Polyphor to accelerate the development of novel antibiotics against multi-drug resistant Gram-negative pathogens
Lire la news
Voir tous les communiqués de Polyphor AG
POLYPHOR AG 
17/07/2018 07:00
EQS-Adhoc: Polyphor announces listing of new shares related to the convertible loan facility agreement with the Wellcome Trust
Lire la news
Voir tous les communiqués de Polyphor AG
POLYPHOR AG 
30/04/2018 07:00
EQS-News: Polyphor announces publication of positive proof of concept data for innovative immuno-oncology candidate balixafortide in The Lancet Oncology
Lire la news
Voir tous les communiqués de Polyphor AG
POLYPHOR AG 
24/04/2018 07:00
EQS-News: Polyphor presents new data at ECCMID on murepavadin and on its novel class of OMPTA antibiotics targeting WHO priority 1 multi-drug resistant pathogens
Lire la news
Voir tous les communiqués de Polyphor AG
POLYPHOR AG 
19/04/2018 07:00
EQS-News: U.S. FDA grants Fast Track designation for Polyphor's innovative immuno-oncology candidate balixafortide in combination with eribulin as third line therapy for metastatic breast cancer
Lire la news
Voir tous les communiqués de Polyphor AG
POLYPHOR AG 
16/04/2018 07:00
EQS-News: Polyphor to present data at the 28th European Congress of Clinical Microbiology
Lire la news
Voir tous les communiqués de Polyphor AG
POLYPHOR AG 
13/04/2018 07:00
EQS-News: Polyphor successfully completes Wellcome Trust collaboration for development of novel antibiotics against multi-drug resistant Gram-negative pathogens
Lire la news
Voir tous les communiqués de Polyphor AG
POLYPHOR AG 
27/03/2018 07:00
EQS-News: Polyphor announces enrollment of first patient in Phase III clinical trial for murepavadin
Lire la news
Voir tous les communiqués de Polyphor AG
POLYPHOR AG 
23/03/2018 11:16
EQS-News: Polyphor presents positive proof of concept data for innovative immuno-oncology candidate balixafortide at European Breast Cancer Conference
Lire la news
Voir tous les communiqués de Polyphor AG

©Dissemination technology Webdisclosure.com - copyright 2022 SYMEX ECONOMICS all rights reserved